Rozrolimupab: Phase II data

A dose-escalation, open-label Phase II trial in 38 evaluable Rhesus D (RhD)-positive, non-splenectomized patients with ITP showed that 75, 100, 125, 150 and 200 µg/kg doses of IV Sym001 produced respo...